Regulation

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">How much is enough?</h1><h2 class="title-bottom webtitle">Digging in to FDA&apos;s scientific dispute about DMD drug Exondys 51</h2><div class="byline">BC Staff</div><div class="date"></div></div></div></div>

How much is enough?

FDA's Woodcock and Unger disagreed on one fundamental question about Exondys 51: how much dystrophin expression predicts clinical benefit in DMD?

Digging in to FDA's scientific dispute about DMD drug Exondys 51

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>